memory loss

ZIP acetate is a novel, cell-permeable inhibitor of protein kinase Mζ (PKMζ), a constitutively active, atypical PKC isozyme involved in LTP maintenance. Selectively blocks PKMζ-induced synaptic potentiation in hippocampal slices in vitro. Reverses late-ph

HTL9936 is an innovative isomeric Muscarinic M1 agonist. This compound is a potential candidate for treating memory loss associated with Alzheimer's disease (memory loss).

MK-0952 is a selective PDE4 inhibitor used to treat long-term memory loss and mild cognitive impairment. It is an intrinsically potent inhibitor and has shown limited whole blood activity.

Amyloid-β (25-35) (Aβ (25-35)) is an 11-residue fragment of the Aβ protein that retains the physical and biological characteristics of the full length peptide. It forms fibrils that react to thioflavin T and Congo red and are organized in a cross-β arrangement of β-strands similar to Aβ (1-40) and Aβ (1-42) fibrils. Aggregated Aβ (25-35) decreases the viability of rat adrenal PC12 cells. It also decreases the viability of primary rat cortical neurons at concentrations ranging from 1 nM to 30 μM. In vivo, intracerebral injection of Aβ (25-35) (20 nmol) in rats induces lesions of neuronal and tissue loss. Aggregated Aβ (25-35) administered intracerebroventricularly to rats induces learning and memory impairments in the Y-maze, novel object recognition, and contextual fear conditioning tests.

Perivine (Perivin) may resolve the instability of the retinoblastoma-associated proteins (RbAp48) complex and thus be used in Alzheimer's disease therapy. Perivine, vobasine, coronaridine and dichomine show hypotensive and muscle relaxant activity.

Arachidoyl ethanolamide, a saturated fatty acyl ethanolamide lacking classical (CB1/CB2) activity, plays a role in a complex system comprising central cannabinoid (CB1), peripheral cannabinoid (CB2), and non-CB receptor-mediated pharmacology. This system has paved the way for extensive research in diverse fields such as memory, weight loss and appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation. Unlike other compounds, Arachidoyl ethanolamide does not bind to the murine CB1 receptor nor does it compete with anandamide for the fatty acid amide hydrolase, the endocannabinoid hydrolytic enzyme. The non-CB receptor-mediated actions of saturated ethanolamides like Arachidoyl ethanolamide are currently under investigation.

PMN310 is a monoclonal antibody targeting β-amyloid oligomers (AβO). It prevents AβO-induced memory formation loss in vivo and reduces synaptic loss and inflammation. PMN310 is applicable in Alzheimer's disease research.

Avenanthramide C is an orally available natural alkaloid with antioxidant/inflammatory properties that reduces the expression of TNF-a, BAK, IL-1b, and Bcl-2; reverses memory and behavioral deficits in Alzheimer's disease, with a reduction in caspase-3 cleavage and an increase in levels of pS9GSK-3β and IL-10, is able to bind α1A adrenergic and stimulate AMPK; can attenuate noise and drug-induced hearing loss.

Novel, cell-permeable inhibitor of protein kinase Mζ (PKMζ), a constitutively active, atypical PKC isozyme involved in LTP maintenance. Selectively blocks PKMζ-induced synaptic potentiation in hippocampal slices in vitro. Reverses late-phase LTP (IC50 = 1